Literature DB >> 15032574

Transcriptional control of early B cell development.

Meinrad Busslinger1.   

Abstract

The generation of B-lymphocytes from hematopoietic stem cells is controlled by multiple transcription factors regulating distinct developmental aspects. Ikaros and PU.1 act in parallel pathways to control the development of lymphoid progenitors in part by regulating the expression of essential signaling receptors (Flt3, c-Kit, and IL-7R alpha). The generation of the earliest B cell progenitors depends on E2A and EBF, which coordinately activate the B cell gene expression program and immunoglobulin heavy-chain gene rearrangements at the onset of B-lymphopoiesis. Pax5 restricts the developmental options of lymphoid progenitors to the B cell lineage by repressing the transcription of lineage-inappropriate genes and simultaneously activating the expression of B-lymphoid signaling molecules. LEF1 and Sox4 contribute to the survival and proliferation of pro-B cells in response to extracellular signals. Finally, IRF4 and IRF8 together control the termination of pre-B cell receptor signaling and thus promote differentiation to small pre-B cells undergoing light-chain gene rearrangements.

Entities:  

Mesh:

Year:  2004        PMID: 15032574     DOI: 10.1146/annurev.immunol.22.012703.104807

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  154 in total

1.  B cell-specific loss of histone 3 lysine 9 methylation in the V(H) locus depends on Pax5.

Authors:  Kristen Johnson; David L Pflugh; Duonan Yu; David G T Hesslein; Kuo-I Lin; Alfred L M Bothwell; Andrei Thomas-Tikhonenko; David G Schatz; Kathryn Calame
Journal:  Nat Immunol       Date:  2004-07-18       Impact factor: 25.606

2.  c-Cbl deficiency leads to diminished lymphocyte development and functions in an age-dependent manner.

Authors:  Chozhavendan Rathinam; Richard A Flavell
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-19       Impact factor: 11.205

3.  SUMO-specific protease 1 is critical for early lymphoid development through regulation of STAT5 activation.

Authors:  Thang Van Nguyen; Pornpimon Angkasekwinai; Hong Dou; Feng-Ming Lin; Long-Sheng Lu; Jinke Cheng; Y Eugene Chin; Chen Dong; Edward T H Yeh
Journal:  Mol Cell       Date:  2012-01-27       Impact factor: 17.970

4.  Lineage determination in the immune system.

Authors:  Ellen V Rothenberg
Journal:  Immunol Rev       Date:  2010-11       Impact factor: 12.988

Review 5.  Contingent gene regulatory networks and B cell fate specification.

Authors:  Harinder Singh; Kay L Medina; Jagan M R Pongubala
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-23       Impact factor: 11.205

6.  Defining the impact of beta-catenin/Tcf transactivation on epithelial stem cells.

Authors:  William E Lowry; Cedric Blanpain; Jonathan A Nowak; Geraldine Guasch; Lisa Lewis; Elaine Fuchs
Journal:  Genes Dev       Date:  2005-06-16       Impact factor: 11.361

7.  Repression of Flt3 by Pax5 is crucial for B-cell lineage commitment.

Authors:  Melissa L Holmes; Sebastian Carotta; Lynn M Corcoran; Stephen L Nutt
Journal:  Genes Dev       Date:  2006-04-15       Impact factor: 11.361

8.  Pax-5 Inhibits NF-κB Activity in Breast Cancer Cells Through IKKε and miRNA-155 Effectors.

Authors:  Jason Harquail; Nicolas LeBlanc; Carine Landry; Nicolas Crapoulet; Gilles A Robichaud
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-07-21       Impact factor: 2.673

9.  Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells.

Authors:  Christopher D Scharer; Colleen D McCabe; Mohamed Ali-Seyed; Michael F Berger; Martha L Bulyk; Carlos S Moreno
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

10.  IL-7 specifies B cell fate at the common lymphoid progenitor to pre-proB transition stage by maintaining early B cell factor expression.

Authors:  Kazu Kikuchi; Hirotake Kasai; Akiko Watanabe; Anne Y Lai; Motonari Kondo
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.